Complete Program Guide can be downloaded here
See below for Agenda, Speakers, and Sponsors for the 2025 event
2025 Agenda
Program Guide can be downloaded here
Topics Include:
Basic & Translational Science of Psychedelics | Clinical Models: Ketamine, Psilocybin, and Ibogaine | Global Practices & Comparative Frameworks | Legal & Policy Pathways for Regulation | Therapeutic Facilitation & Patient Journeys | Coverage Models & Health System Integration | Industry & Manufacturing Perspectives | Economics of Psychedelic Therapies | Patient Perspectives & Family Narratives | Future Directions: Implementation, Barriers, & Spirituality
Speakers
Keynote Speaker
Psilocybin, Ibogaine, and Ketamine: the Basic and Translational Science
Professor of Psychiatry,
Perelman School of Medicine
How Ketamine/Esketamine Opened the Doors to Psychedelics Research
Research Assistant Professor of
Psychiatry, Perelman School of Medicine
Penn’s Clinical Trial of Psilocybin for OUD
Professor of Chemistry and The Zuckerman Mind Brain Behavior Institute, Columbia University
Mechanisms of Ibogaine and Multidimensional Therapeutic Potential
Adjunct Professor of Psychiatry, Perelman School of Medicine
Long Day's Journey into Psilocybin Research: Local and Regional Barriers (Virtual)
Therapeutic and Clinical Perspectives
Therapeutic and Clinical Applications
Medical Director, Inscape Recovery
Current Modes of Ibogaine Practice in Mexico (Virtual)
Patrick Fishley, RN BScN CCRN
& Michele Fishley, LPN
Iboga Practitioners, Soul Reflections Int'l
Road Maps and Barriers to adding Ibogaine to the US Model (Virtual)
Physician; Veracruz do Brasil
Ibogaine’s Clinical Success in Brazil, and Legal Roadblocks Beyond Drug Scheduling (Virtual)
Hospitalist, Jamaica Hospital Medical Center; Founder and Executive Director, MediRootz Medical Group
Clinical Perspectives in the Implementation of Ibogaine-assisted Therapy
Founder, The Mission Within treatment center
5-MeO-DMT Treatment Applications (Virtual)
Psilocybin-Assisted Therapy Educational Play
Editor of Netflix’s How to Change Your Mind;
CEO, Psychedelic Oncology;
Founder, NJ for Fungi and Plant Medicines
Therapist, New Jersey Psychedelic
Therapy Association
Physician; Psychedelic Oncology; Memorial Sloan Kettering Cancer Center
Public and Private Coverage Models
Enthea; California Institute of Integral Studies; Psychedelic Research Group
Founder, CannaCoverage of Trenton, NJ
Chief of Staff, Journey Clinical
Independent KAT Clinician
Legal Considerations
Attorney, Law Office of Robert T. Rush;
Rights and Reason Project
DEA vs. Psychedelic Science: The Fight to Save DOI
Executive Director, Coalition for
Medical Marijuana-NJ;
Chairman, Trenton Cannabis Advisory Committee
Panelist: Current Legal Frameworks
Attorney, Owner, Phelps Law Office;
Students for Sensible Drug Policy
Panelist (Virtual): Panelist: Current Legal Frameworks
Educational Outreach Director,
Mass Healing
Victory from the Jaws of Defeat -
Hard Lessons from a Failed Ballot Measure Campaign
Patient Experiences
End-of-Life Doula;
Certified Dementia Care Specialist
Veteran, United States Air Force
(2001-2007)
Coalition for Medical Marijuana-NJ, Inc.;
Americans for Safe Access
Advocate for cannabis and alternative plant therapies for Veterans, first responders, and law enforcement
Heroic Hearts Project
Board-Certified Psychiatric-Mental Health Nurse Practitioner
Clusterbusters / FDNY (ret.)
Pharmaceutical Perspectives
Facilitator, cultivater, manufacturer;
CEO & Founder, Psylutions
Building Natural Psilocybin Medicine for Real Patient Journeys
Tribute to Norma Lotsof
The Penn Psychedelics Collaborative honors Norma Lotsof, whose lifelong dedication helped bring ibogaine from the margins of underground discovery into the modern dialogue on addiction treatment and psychedelic medicine. Together with her late husband, Howard Lotsof, Norma’s advocacy, compassion, and perseverance laid the foundation for much of the ibogaine research and practice that exists today. Norma now faces significant medical and financial challenges, and the global ibogaine community has come together to support her through this GoFundMe campaign. We invite our community to join in honoring her extraordinary contributions and helping ensure she receives the care and dignity she deserves.
Tribute to Nolan R. Williams, MD
The Penn Psychedelics Collaborative honors Nolan R. Williams, MD, was a pioneering psychiatrist and neuroscientist whose work transformed how we think about treating severe mood disorders, particularly through his leadership in ibogaine research. As Director of the Stanford Brain Stimulation Lab, he helped design and study carefully monitored ibogaine protocols for veterans and others living with depression, PTSD, traumatic brain injury, and substance use disorders, documenting rapid, sustained reductions in mood and trauma symptoms after a single treatment. By pairing ibogaine with sophisticated brain imaging and electrophysiology, he began to map how this powerful medicine reshapes neural circuits involved in mood, opening new paths toward safer, more precise therapies. Nolan’s work offered hope to people who had exhausted conventional options, and his blend of scientific rigor, clinical courage, and deep compassion continues to guide the emerging field of ibogaine assisted care for mood and trauma related disorders.